Prior work has shown that kappa opioids may attenuate the effects of analgesic ì receptor agonists in some neural circuits related to pain modulation. This study examined whether hypoalgesia following exposure to a signal for shock is attenuated by infusions of the k agonist U69593 into the rostral ventromedial medulla (RVM). Rats were trained with paired or unpaired presentations of white noise and foot shock. On test days, tail¯ick latencies were measured before, during, and after exposure to the auditory conditioned stimulus (CS). One of three doses of U69593 (0.0445, 0.178 and 1.00 ìg) or an equivalent volume of saline was injected into the RVM. Rats that had received noise-shock pairings displayed conditional hypoalgesia (CHA) compared to those given unpaired presentations. Expression of CHA was completely blocked by the highest dose of U69593 (1.00 ìg) injected 20 min before testing, indicating an antagonistic effect of U69593 on expression of CHA. These ®ndings are discussed in terms of the evidence for antagonism of morphine-and DAMGO-induced hypoalgesia by k agonists. NeuroReport
INTRODUCTION
Nociceptive re¯exes, such as tail withdrawal from radiant heat, may be modulated by the activity of a series of interconnected neural circuits located in the amygdala, periaqueductal gray (PAG), rostral ventromedial medulla (RVM) and dorsal horn of the spinal cord [1±6] . Chemical or electrical stimulation of each of these sites can result in antinociception and inhibition of activity in spinal cord neurons responsible for rostral transmission of pain [1, 7] . In addition, the amygdala, PAG and RVM have also been shown to play a critical role in mediating antinociception evoked by environmental stressors and conditional hypoalgesia (CHA) evoked by learned danger signals. For example, rats trained with a conditional stimulus (CS) that signals the delivery of electric shock display hypoalgesia in the presence of the CS. However, expression of CHA is abolished by lesions of either the PAG or RVM [4±6,8±10] .
Within the RVM, the neural circuits related to antinociception rely on both opioid and non-opioid transmitters [11, 12] . One focus of pharmacological studies looking at medullary opioid mechanisms of pain inhibition has been to determine whether there are differential roles for opioid receptor subtypes. Invariably, the results have indicated involvement of ì receptors in the RVM [13±17]. In our previous studies, we have shown that CHA elicited by an auditory stimulus that had been paired with foot shock is expressed through ì receptors in the RVM. Expression of this antinociceptive response was blocked by the ì-selective antagonist CTAP [14] or by chronic pretreatment with an antisense oligodeoxynucleotide probe targeting exon 1 of the ì-receptor clone MOR-1 [15] .
Recent evidence has shown that k agonists can modulate hypoalgesia induced by exogenously applied ì opioids, such as morphine and DAMGO [18±20]. For example, Pan et al. [19] found that infusion of U69593 into the RVM blocked the hypoalgesia effects of DAMGO microinjections into the PAG. Further, they showed that the attenuating effects of U69593 were due to its actions on k receptors, because administration of the k antagonist nor-BNI prior to U69593 prevented the attenuating effects of the agonist. Moreover, there is electrophysiological evidence that U69593 and met-enkephalin, a ì/ä agonist, act to inhibit two distinct subpopulations of neurons in the same medullary area [19] . Anatomically, the distribution of ì and k receptors overlap substantially in the RVM and the PAG, providing the structural basis for interactions between these opioids [21] . Since we have previously shown that CHA is mediated by ì receptors at the RVM, the present investigation sought to determine whether this antinociceptive response is attenuated by infusions of the k agonist U69593 into the RVM.
MATERIALS AND METHODS
Thirty-four male Long±Evans rats (Harlan Sprague Dawley, Madison, WI), with an average weight of 400 g (range 330±480 g) were housed individually in suspended stainless steel cages and allowed free access to rat chow and water. The colony room was maintained on a 14:10 h light:dark cycle, with behavioral testing conducted during the light portion. The rats were handled for several days before RVM cannulations. The anaesthetic, surgical, and histological procedures, and apparatus used were identical to those employed previously and have been described elsewhere [14, 15] . After surgery, the rats were allowed at least 5 days to recover before exposure to three consecutive days of training. On each of days 1±3 the rats were placed in conditioning chambers and given either eight paired or unpaired presentations of white noise (WN; 72 dB, 30 s) and foot shock (1 mA, 1 s). Each training session began with 8 min during which no stimuli were presented, followed by presentations of WN every 2 min. For the paired condition, foot shock was delivered immediately following the termination of WN. For the unpaired condition, foot shock was delivered 30 s after the termination of WN. The rats were left in the chambers for 6 min after the last foot shock, with each training session lasting $30 min. The chambers were cleaned with 10% ammonium solution after each session to mask any stress odors. On day 3, the rats were also familiarized for 1.5 h to the restraining tubes used in the tail¯ick (TF) test in a dimly lit room. On day 4, they were familiarized to the TF testing procedure. The rats were brought to the laboratory, placed in the restraining tubes and, 10 min later, were given 10 TF trials at 2 min intervals. On day 5, the rats were tested to determine the effects of U69593 on the expression of CHA. They were brought to the laboratory and placed in a restraining tube. After 10 min of adaptation, they were given eight TF trials at 2 min intervals. The ®rst three trials consisted of baseline TF latencies (TFLs). At the start of the fourth trial the rats were injected with either saline or U69593. On the ®fth trial WN was presented for 30 s, starting 15 s before the onset of radiant heat, so as to co-terminate with the 15 s cut-off latency. Three post-CS trials (6±8) were conducted. On day 6, the rats were re-tested using the same procedure, except that saline or U69593 was injected before placement in the TF restraining tubes. Thus, on the second test day there were four post-injection trials (1±4), a CS trial (5), and three post-CS trials (6±8). This test was conducted because the results from the ®rst test day suggested that a longer interval between infusion of U69593 and presentation of CS might have been required to better detect any effects of the drug on expression of CHA. The concentrations and volumes of U69593 (Sigma) used were 0.178 ìg/ìl (0.25 and 1.00 ìl) and 1.00 ìg/ìl (1.00 ìl). The intermediate dose Bregma-11.00
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Gi (0.178 ìg) was selected because it was effective in attenuating hypoalgesia induced by infusions of DAMGO into the PAG [19] .
RESULTS
Eight subjects were excluded because cannulae placements were outside the RVM. The ®nal group size was six in unpaired, saline (sal) and ®ve in each of the other four groups. Figure 1 shows the injection sites for subjects in each of these groups. Figure 2 shows the mean TFLs across trials for the groups on the ®rst (left panel) and second (right panel) test days. This data was analysed using ANOVAs with group as the between subjects factor. There were reliable differences in TFLs on the baseline trial of the ®rst test (F 4.46, p , 0.01) and on the CS trial of both tests (F 2.88 and 6.39, p , 0.01). Tukey's post-hoc comparisons between means on the baseline trial of the ®rst test revealed signi®cant differences between rats given the highest drug dose (1.00 ìg) and those given saline ( p , 0.05). Rats given the highest dose of U69593 (1.00 ìg) also differed signi®cantly from those given the lowest drug dose (0.0445 ìg) on this trial ( p , 0.01). As can be seen from the left panel of Fig. 2 , rats given U69593 (1.00 ìg) displayed the shortest baseline TFLs. On the CS trial of the ®rst test, the analysis con®rmed that rats given the lowest drug dose (0.0445 ìg) displayed signi®cantly longer TFLs than those in group unpaired, sal ( p , 0.05). On the CS trial of the second test (right panel, Fig. 2 ), rats in paired, sal displayed signi®cantly longer TFLs than those in unpaired, sal ( p , 0.01), con®rming expression of CHA. Expression of this response was unaffected by the intermediate drug dose, because rats in paired, U69593 (0.178 ìg) showed the same long TFLs as those displayed by rats in paired, sal. In contrast, expression of CHA was reduced by the other two doses of U69593. The lowest dose partially attenuated expression of CHA, because group paired, U69593 (0.0445 ìg) did not differ signi®cantly from either of the saline groups ( p . 0.05). The highest dose blocked expression of CHA, because rats in paired, U69593 (1.00 ìg) displayed the same short latencies as those shown by rats in unpaired, sal, which were signi®cantly shorter than the TFLs of rats in paired, sal ( p , 0.05).
DISCUSSION
The present results con®rm that an auditory signal paired with shock becomes capable of eliciting hypoalgesic responses [8, 22, 23] . Speci®cally, rats trained with WN-shock pairings displayed longer TFLs to the auditory CS than those trained with separate exposures to WN and shock. Further, we have shown that expression of CHA was completely prevented by infusions of a high dose of U69593 (1.00 ìg) into the RVM and partially attenuated by infusions of a lower dose (0.0445 ìg). These ®ndings, therefore, demonstrate the antagonistic effects of U69593 on ì-mediated hypoalgesia produced by the release of endogenous opioids, and extend previous observations of similar antagonisms by k agonists on hypoalgesia induced by exogenous ì opioids [18±20]. However, a comparison of the present results with those reported by Pan et al. [19] suggests that a higher drug dose was required to attenuate expression of CHA than DAMGOinduced hypoalgesia. Speci®cally, Pan et al. [19] found that hypoalgesia induced by infusions of DAMGO into the PAG was partially attenuated by pretreatment of the RVM with 0.178 ìg (in a volume of 1.00 ìl). The attenuation was not detected immediately after injection of DAMGO, but 10 min later and was evident throughout the remaining 20 min of TF testing. In contrast, we did not ®nd any evidence for attenuation of CHA using the same concentration and volume of U69593 given either 4 min (®rst test) or 20 min (second test) before presentation of WN. Although the present results indicated that a smaller volume (0.25 ìl) of this concentration (0.178 ìg/ìl) partially attenuated expression of CHA when given 20 min before presentation of WN, the effect was not well de®ned. There was also no evidence that the highest drug dose (1.00 ìg) affected expression of CHA when given 4 min before presentation of WN. However, the highest drug dose (1.00 ìg) blocked expression of CHA completely when given 20 min before the CS.
Both the present results and those reported by Pan et al. [19] have shown that the antagonistic effects of k agonists on ì-mediated analgesia takes at least 10±20 min to become evident. Pan et al. [19] have suggested a model for the interaction between ì and k agonists, based on the ®ndings that k agonists U69593 and dynorphin selectively hyperpolarized one type of medullary neuron (primary cells), that these neurons have a GABAergic output and are inhibited by ì ligands and that met-enkephalin, a ì/ä agonist, selectively hyperpolarized another type of medullary neuron (secondary cells). These cell types have opposing functions, with activation of primary cells inhibiting pain transmission, and activation of secondary cells facilitating pain transmission. According to this model, ì agonists inhibit pain transmission in two ways: by disinhibiting primary cells from GABAergic inhibition, and by directly inhibiting secondary cells. In contrast, k agonists are thought to act selectively to inhibit primary cells, thereby producing the opposite effect of facilitating pain transmission. Future studies might investigate if these mechanisms function according to different temporal parameters and whether their antagonistic effects are general to other brain regions. In summary, the present ®ndings have demonstrated that infusions of a high dose of the k agonist U69593 into the RVM completely blocked expression of ì-mediated CHA. These results have provided new evidence for the antagonistic effect of U69593 on endogenous ì opioids, extending previous ®ndings of similar antagonisms of k agonists on exogenous ì opioids. Although U69593 is an agonist selective for k receptors, future studies might con®rm that the attenuation observed is k-mediated by demonstrating a reversal of this attenuation with a k antagonist (e.g. nor-BNI).
